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Objectives. The transvascular closure of patent foramen ovale (PFO) with self-expanding devices carries the risk of left atrial
thrombus formation related to material protruding into the left atrium. Thus, we developed a novel device with ﬂat left atrial
disc geometry. We evaluated feasibility, handling, and biocompatibility in a porcine animal model. Methods. Implantation of an
Occlutech Figulla PFO device was performed in 10 mini pigs using ﬂuoroscopy and intra-cardiac ultrasound after transseptal
puncture of the interatrial septum. Angiographic follow-up was performed after six and twelve weeks. Results. Implantation was
successful in 100%. There were no further implant related complications. One procedure related death occurred, as one animal
died of ventricular tachycardia due to mispunture of the interatrial septum. Angiographic studies showed no residual shunt during
follow-up. Histopathological evaluation could demonstrate partial neoendothelialization after 6 weeks with completion after 12
weeks. The devices were incorporated into connective tissue containing ﬁbro muscular cells. An only mild inﬂammatory reaction
was detected locally related to the polyester ﬁbers. Conclusion. In terms of feasibility and handling, the new device does not seem
to be inferior to other presently used implantation systems. Good biocompatibility was demonstrated with rapid and complete
neoendothelialization.
Copyright © 2009 F. Krizanic et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.Introduction
The patent foramen ovale is an open passageway between the
superior limb of the septum secundum ofthe right atrial side
and the septum primum of the left atrial side. It represents
thephysiologicalinteratrialcommunicationthroughoutfetal
life.
Functional closure occurs immediately after birth which
is usually followed by anatomical closure within the ﬁrst
weeks postnatally. In about 27% of humans, this anatomical
fusion does not occur [1]. In case of a right-to-left shunt,
paradoxical embolism may occur with the result of transient
ischemic attack or stroke. In 35–44% of patients with
ischemic stroke the origin remains unknown (cryptogenic)
[2]. Several studies have shown that the prevalence of a
PFO in these patients is signiﬁcantly higher than in control
groups. Whereas a PFO is found in 44–66% of patients with
cryptogenic stroke, in patients with known causes of stroke
it is found in only 9–27%. There is a high recurrence rate of
a second thromboembolic event despite medical treatment
ranging between 2% and 15% per year, especially in the age
group >55 years. With this high prevalence, there is a need
for preventative measures in the elderly [3].
Transcatheter interventional closure of a patent foramen
ovale has become a routine procedure in adults with a
low risk of periprocedural complications and good long-
term results in a large retrospective study [4–7]. Since the
ﬁrst implantation of an occlusion device into an intra-atrial
communication in 1976 [8], diﬀerent device systems have
been designed to improve feasibility, eﬃcacy, and safety.
2. Methods
2.1. Occlutech Figulla PFO Device. The device consists of a
nitinol wire mesh (0.12mm) forming two ﬂexible retention
discs (diameter 23/25mm) using a braided unique technol-
ogy which allows forming a single hub on the proximal
side (Figures 1 and 2) .T h em a t e r i a li sc h a r a c t e r i z e db y2 Cardiology Research and Practice
Figure 1: View of the Occlutech Figulla PFO device (23/25mm)
prior to implantation.
Figure 2: View of the Occlutech Figulla PFO device (23/25mm)
prior to implantation.
a shape memory eﬀect which allows self-expansion. The
two discs are linked by a 3mm central waist. Two PET
patches (polyethylenterephtalat) assure complete closure
after implantation.
The novelty is that the left atrial disc only consists of a
single layer wire mesh without having a hub which therefore
minimizes the amount of material on the left atrial side.
2.2. Animal Model. The aim of present study was the
implantation of a PFO device in Goettingen mini pigs, which
are frequently used as animal model for the experiments
closely related to human medicine. Artiﬁcial creation of PFO
in piglets is feasible by percutaneous atrial septal puncture.
PFO prevalence in mini pig is identical to humans, and
the microscopic structures are very similar to humans [9].
The mini pig PFO model appears useful to evaluate new
interventional closure technologies due to comparability in
microscopic features. The implantation of a device in an
naturallyexistingatrialseptaldefectwouldbeamorerealistic
test than artiﬁcial creation, but therefore a larger number of
animals in consideration of PFO prevalence would have been
needed.
Preprocedural anaesthesia was achieved by sedation
with 10mg/kg ketamine and 0.4mg/kg xylazin; the animals
underwent endotracheal intubation using propofol and were
mechanically ventilated with 1-2% isoﬂurane and 30% N2O.
Electrocardiogram, invasive blood pressure measurement,
heart rate, oxygen saturation, tidal volume, and end-tidal
CO2 were monitored. Implantation was performed in 10
mini pigs (mean weight 36kg, mean age 18 months) under
guidance of ﬂuoroscopy and by intracardiac echocardio-
graphy (ICE). After transseptal puncture of the intera-
trial septum with an transseptal needle inside a catheter
(Brockenbrough guidance sheath with transseptal punture
set (Brockenbrough Needle, Medtronic, Inc. Mounds View,
Minnesota) using a nine-French delivery system sheath, the
artiﬁcial defect was passed with a 150cm long guidewire. It
was inserted into the left atrium till reaching the upper left
pulmonary vein after giving of heparin 200U/kg.
The device was loaded and advanced via the guiding
sheath under ﬂuoroscopic control. After deployment of the
left atrial disc the system was pulled back and was ﬁnished
by deployment of the proximal disc on the right atrial side. A
relevant residual shunt was excluded by injection of contrast
media before disconnection of the occluder.
Clopidogrel 75mg (3 months) and acetylsalicylacid
100mg (6 months) per day were administered after implan-
tation.
Allminipigsreceivedhumancareincompliancewiththe
“guide for the care and use of laboratory animals” published
bytheUSNationalInstitutesofHealth(NIHPublicationNo.
85–23, revised 1996). The study was approved by the local
governmental animal ethics committee.
2.3. Follow-up Examination. Angiographic follow-up exam-
inations were performed in one animal after six weeks and
in eight animals after twelve weeks. After the angiography,
the animals were killed by intravenous administration of
potassium chloride.
2.4. Tissue Preparation. The tissue block containing the
implant was ﬁxed in formalin (buﬀered 4%) for histological
examination and embedded in the hard resin methyl-
methacrylat (Technovit 9100; Kulzer & Co, Wehrheim,
Germany). After hardening of the resin, the specimen was
subsequently sectioned in slices of 0.8 mm using a diamond
cutter. These slices were ground down to 10–30 µmb ya
rotational grinder as previously described [10]. Staining of
the specimen was performed with Richardson blue.
3. Results
Implantation was successful in all animals (100%; n =
10/10). The mean time from intubation to device implan-
tation was 138.9 ± 42 minutes. The procedure time varied
considerably due to the diﬀerent anatomical features of the
porcine and the human intra-atrial septum.
Two of the 10 animals died ahead of scheduled end
of the experiments. One mini pig died in cardiogenic
shock due to ventricular tachycardia which was caused by
recurrent mispuncture of the IAS after completion of the
implantation procedure. A second animal died in respiratory
failureduetopneumoniaafter3months.Anotherlaboratory
animal developed transient pericardial eﬀusion without
hemodynamicrelevance,whichresolvedwithouttherapeutic
intervention.
The mean implantation time was 127 ± 46 days. Angio-
graphic studies during followup showed no relevant residual
shunt.Cardiology Research and Practice 3
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Figure 3: Macroscopic aspect of the right atrial disc (a), and the left
atrial disc (b) of an explanted Occlutech Figulla PFO device after an
implantation time of 12 weeks. Both discs are completely covered
by ﬁbrous tissue without any thrombus deposition.
Figure 4: The central pin represents the right atrial hub without
signs of corrosion.
3.1. Macroscopic Examination. The devices were covered
with a thin shining layer of whithish tissue (Figure 3). On
the right atrial side coverage was complete; on the left atrial
side small areas were covered incompletely depending on
the diﬀerent anatomical structures in comparison to human
heart because of the intra-atrial septum diameter which
led to incomplete adaptation. Nevertheless no thrombus
formation could be detected on the surface.
No deformations or wire strut fractures could be seen
macroscopically or under ﬂuoroscopic control.
3.2. Histology. Metal struts of the nitinol wire mesh and
the right atrial central hub were smooth without signs of
corrosion (Figure 4). The implant was incorporated in dense
connective tissue containing ﬁbromuscular cells, capillaries,
and small vessels (Figure 5).
Some multinucleated foreign body giant cells were found
neighbouring the polyester ﬁbres (Figure 6). Circumscribed
mild lymphocytic inﬁltration was observed with a loose
distributionwithintheimplant,butconstantlylocallyrelated
to the polyester ﬁbres.
4. Discussion
It is appreciated that a PFO is a frequent cause of cerebral
embolism. Until today there is a continuous debate as to
how these patients should be treated [11–13]. Multiple data
point to higher prevalence of PFO in patients with a second
cryptogenic stroke and in patients older than 55 years and
Figure 5: Micrograph of metal struts of the occluder (black) on the
right atrial side. The struts are completely covered by ﬁbrous tissue
and endothelium. Magniﬁcation 100×, Richardson blue staining.
Figure 6 :T h eP E T - p a t c ho nt h el e f ta t r i a ls i d e( a r r o w s )i s
completely covered by ﬁbrous tissue and endothelium without
majorinﬂammatoryreactions.Magniﬁcation16×,Richardsonblue
staining. PET: polyethylenterephtalat.
those with septal aneurysm [14–16]. An additional risk of
stroke recurrence is presented by a large PFO defect diameter
[17, 18].
Many diﬀerent PFO occlusion devices are marketed
currently with remarkable diﬀerences in device design.
Protrusion of implant material on the left atrial side could
be identiﬁed as a risk factor for thrombus formation or even
thromboembolism after interventional therapy of a PFO
[19–22]. Thus we developed a new PFO occlusion device
made from a nitinol meshwork using a unique patented
braiding technology with reduces left atrial foreign material.
It is regarded mandatory to examine biocompatibility
of human implants prior to introduction into clinical use
[23]. In the present study, the device was implanted in
10 Goettingen mini pigs. Macroscopic, angiographic, and
histopathological followup did not show any superﬁcial
thrombus formation, wire fractures, or major inﬂammatory
reactions.
Nevertheless, few lymphocytic inﬁltrations and some
foreign giant body cells neighbouring the polyester ﬁbres
were seen in the implant. The extent of inﬂammatory
reactions was similar to those described for other devices
[24, 25]. Overall, good biocompatibility of this novel PFO
occluder could be demonstrated in our study. Long-term
observations have to answer the question if the improved
geometry of the left atrial disc can reduce thromboembolic
complications following interventional PFO closure.4 Cardiology Research and Practice
Perfecting device technology together with advanced
identiﬁcation of patients who mostly beneﬁt from interven-
tional therapy will further improve the outcome of patients
with PFO.
5. Conclusion
The Occlutech Figulla PFO device appears to be safe and
feasibleforpercutaneousPFOclosure.Furthermore,thedata
presented demonstrate good biocompatibility of the device
and therefore complement the ﬁrst positive clinical data
[26].
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